Findings

What do systematic reviews say?

1,835 questions · 1,886 findings · 74 reviews · Skin

Sort:Best matchNewestHighest certainty Download CSV

No studies found 542 · 28.7%GRADE not reported 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

R‐salbutamol 0.5% topical cream vs placebo

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

R‐salbutamol 0.5% topical cream vs placebo

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluocinonide 0.05% vs hydrocortisone 1%

At least 50% reduction in erythema · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

R‐salbutamol 0.5% topical cream vs placebo

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Moderate

Tacrolimus 0.1% cream vs placebo

Clearing or excellent improvement · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

At least 50% reduction in erythema · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Moderate

Fluocinonide 0.05% vs hydrocortisone 1%

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluocinonide 0.05% vs hydrocortisone 1%

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluocinonide 0.05% vs hydrocortisone 1%

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 78 participants
Moderate

Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily

Clearing or excellent improvement · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily

At least 50% reduction in erythema · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Imiquimod vs vehicle

Short‐term clinical cure (up to 3 months after start of treatment) (completely cleared short term) · molluscum contagiosum

Imiquimod showed no clear difference in short‐term clinical cure (up to 3 months after start of treatment)… compared with vehicle (moderate certainty).

1 finding from 1 review

Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
RR 1.33 [0.92, 1.93]
4 studies · 850 participants
Moderate

Imiquimod vs vehicle

Medium‐term clinical cure (after 3 months and up to 6 months after start of treatment) (completely cleared medium term) · molluscum contagiosum

Imiquimod showed no clear difference in medium‐term clinical cure (after 3 months and up to 6 months after… compared with vehicle (moderate certainty).

1 finding from 1 review

Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
RR 0.88 [0.67, 1.14]
2 studies · 702 participants
Moderate

Imiquimod vs vehicle

Long‐term clinical cure (beyond 6 months after start of treatment) (completely cleared long term) · molluscum contagiosum

Imiquimod showed no clear difference in long‐term clinical cure (beyond 6 months after start of treatment)… compared with vehicle (moderate certainty).

1 finding from 1 review

Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
RR 0.97 [0.79, 1.17]
2 studies · 702 participants
Moderate

Imiquimod vs vehicle

Short‐term clinical improvement (up to 3 months after start of treatment) · molluscum contagiosum

Imiquimod showed no clear difference in short‐term clinical improvement (up to 3 months after start of… compared with vehicle (high certainty).

1 finding from 1 review

Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
RR 1.14 [0.89, 1.47]
4 studies · 850 participants
High